SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

"Without the glasses you can't see a thing, put the glasses on you can suddenly see. You get that wow factor every time you do it." Philip Booth, 60, has had bionic eyes for the last three and a half ...

Second Sight announced in a press release the publication of positive results from a long-term clinical trial of the Argus II Retinal Prosthesis System. According to the press release, the five-year ...

More than 350 people have a discontinued retinal implant in their eyeballs. The invention was once a cutting-edge option for restoring sight, but it has been replaced by newer technologies. The ...

Please provide your email address to receive an email when new articles are posted on . There are revolutionary advances in surgery — radical shifts that change the trajectory of a field — and ...

., the world’s leading developer and manufacturer of retinal prostheses, today announced that a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel has been scheduled to review ...

The Argus II, a “bionic eye”, is intended to provide electrical stimulation of the retina to elicit visual perception in blind subjects with severe to profound retinitis pigmentosa, according to the ...

USC and Second Sight Medical Products Inc., the developer of retinal prostheses for treating blindness, are expanding the clinical trial of an advanced retinal prosthesis into Europe. The announcement ...